{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:00:11Z","timestamp":1781107211936,"version":"3.54.1"},"reference-count":18,"publisher":"Solen s.r.o.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["\u010ces. slov. farm.","Czech and Slovak Pharmacy"],"published-print":{"date-parts":[[2026,6,10]]},"DOI":"10.36290\/csf.2026.019","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:24:22Z","timestamp":1781105062000},"page":"108-111","source":"Crossref","is-referenced-by-count":0,"title":["Atrasentan: new molecule in the therapy of IgA nephropathy and other glomerulopathies"],"prefix":"10.36290","volume":"75","author":[{"given":"Silvie","family":"Rajnochov\u00e1 Bloud\u00ed\u010dkov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21073","reference":[{"key":"ref0","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae214"},{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2025.151573"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30772-X"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010080869"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf066"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02208"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13245"},{"issue":"8","key":"ref7","first-page":"2965","article-title":"Phase I dose-escalation study of the safety and pharmacokinetics for refractory prostate cancer","volume":"8","author":"Zonnenberg BA","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref8","article-title":"FDA rejects Abbott's prostate cancer drug Xinlay","author":"PharmaTimes","year":"2005","journal-title":"PharmaTimes"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07340521"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.09.026"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2025.101078"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.10.004"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.20251m9dyn78"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad063c_4341"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.02.1088"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2024sd7jz4q0"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2025.02.0448"}],"container-title":["\u010cesk\u00e1 a slovensk\u00e1 farmacie"],"original-title":["Atrasentan: nov\u00e1 molekula v l\u00e9\u010db\u011b IgA nefropatie a jin\u00fdch glomerulopati\u00ed"],"link":[{"URL":"http:\/\/csfarmacie.cz\/doi\/10.36290\/csf.2026.019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:24:27Z","timestamp":1781105067000},"score":1,"resource":{"primary":{"URL":"http:\/\/csfarmacie.cz\/doi\/10.36290\/csf.2026.019.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6,10]]}},"URL":"https:\/\/doi.org\/10.36290\/csf.2026.019","relation":{},"ISSN":["1210-7816","1805-4439"],"issn-type":[{"value":"1210-7816","type":"print"},{"value":"1805-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]}}}